Nurtec (Rimegepant) for Migraine Prevention
For preventive treatment of episodic migraine, take Nurtec (rimegepant) 75 mg orally every other day, using the orally disintegrating tablet formulation. 1
Dosing Schedule
The FDA-approved preventive dosing is straightforward:
- 75 mg every other day (not daily)
- Place the orally disintegrating tablet on or under the tongue
- No water needed—it dissolves in saliva
- Maximum one dose per calendar day 1
Important: When used preventively, you can also use rimegepant as needed for acute migraine attacks on non-scheduled dosing days, but still limited to one 75 mg dose per 24-hour period 1. This dual-use capability makes rimegepant unique among migraine medications.
When to Consider Preventive Treatment
Consider initiating rimegepant for prevention when patients experience:
- Frequent episodic migraines that impair quality of life despite optimized acute therapy
- Typically ≥2 days per month of migraine-related disability 2
- Contraindication to or failure of acute treatments
- Overuse of acute medications 3
Expected Timeline for Efficacy
Set realistic expectations: Preventive benefit may appear within the first 4 weeks, but full assessment requires 3-6 months of treatment 2, 4. Recent meta-analyses show rimegepant significantly reduces monthly migraine days in the first month (mean reduction of 1.49 days), with sustained benefit over 12 weeks 4. Do not discontinue prematurely due to perceived lack of efficacy in the first few weeks.
Contraindications
Absolute contraindication:
- History of hypersensitivity reaction to rimegepant or any component, including anaphylaxis, dyspnea, or rash (reactions can occur days after administration) 1
Critical Drug Interactions Requiring Dose Adjustment
Avoid entirely:
- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)
- Strong or moderate CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine)—these reduce efficacy 1
Requires 48-hour spacing:
- Moderate CYP3A4 inhibitors (e.g., fluconazole, verapamil, diltiazem)
- Potent P-glycoprotein inhibitors (e.g., cyclosporine, quinidine) 1
When using these moderate inhibitors, skip the next scheduled dose if it falls within 48 hours of the interacting medication.
Safety Monitoring
Monitor for:
- Hypertension: Development of new-onset hypertension or worsening of pre-existing hypertension has been reported with CGRP antagonists, including rimegepant 1. This is particularly important in patients with cardiovascular risk factors.
- Hepatic function: While aminotransferase elevations >3x upper limit of normal occurred in 0.9% of patients in long-term studies, none had concurrent bilirubin elevations suggesting serious hepatotoxicity 5
- Delayed hypersensitivity reactions: Can occur days after administration 1
Special Populations
Pregnancy and lactation: Discuss adverse effects during pregnancy and lactation with patients of childbearing potential 6. The evidence base for safety in pregnancy is limited.
Positioning in Treatment Algorithm
Based on the most recent 2025 ACP guidelines, rimegepant occupies a specific niche:
- For acute treatment: Consider rimegepant as a third-line option for moderate to severe episodic migraine in patients who do not tolerate or have inadequate response to combination therapy of a triptan plus NSAID or acetaminophen 7
- For prevention: The 2025 ACP prevention guideline does not specifically rank rimegepant among first-line preventive agents (which include propranolol, amitriptyline, topiramate, and valproate) 6, but its unique dual-use capability and favorable tolerability profile make it valuable for patients requiring both acute and preventive therapy
Practical Advantages
Rimegepant offers several clinical benefits:
- No vasoconstriction: Unlike triptans, rimegepant does not cause coronary or intracranial artery vasoconstriction, making it safer in patients with cardiovascular disease 8, 9
- Rapid absorption: Supports quick onset for acute treatment while maintaining a 10-hour half-life for sustained efficacy 8
- Oral disintegrating formulation: Convenient for patients with nausea or difficulty swallowing 9
- Can be combined with triptans: No clinically meaningful blood pressure elevation or pharmacokinetic interactions when co-administered 8
Long-term Use
Long-term safety data up to 52 weeks show sustained effectiveness with favorable tolerability 5. The most common adverse events are nasopharyngitis (25.1%) and nausea (approximately 2x placebo rate) 5, 4. Discontinuation due to adverse events is low (1.3%) 5.
Consider pausing treatment after 6-12 months of successful prevention to determine if ongoing therapy remains necessary, minimizing unnecessary drug exposure 2.
Cost Considerations
The 2025 ACP guideline emphasizes prescribing less costly medications when multiple options have similar efficacy 6. Rimegepant is significantly more expensive than traditional preventive agents (propranolol, amitriptyline, topiramate, valproate). However, its dual-use capability may offset costs by eliminating the need for separate acute medications in some patients.